Tandem therapy for retinoblastoma: Immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1357-1372

  Liu, Qiuling ^a   Wang, Yafeng ^a,b   Wang, Han ^c   Liu, Yingying ^c   Liu, Tao ^c   Kunda, Patricia Elena ^c  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c Poten Biomedical Institute for Cancer Immunotherapy   (China)

Author keywords

Annexin V; Apoptosis; Carboplatin; Cytokine induced killer cells; Dendritic cells; Retinoblastoma

Indexed keywords

CARBOPLATIN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; CELL POPULATION; CELL THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; PRIORITY JOURNAL; RETINA CELL; RETINOBLASTOMA; TIME-LAPSE VIDEO MICROSCOPY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICROSCOPY, FLUORESCENCE; RETINOBLASTOMA;

EID: 84880896916     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1448-7     Document Type: Article

References (55)

1. Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS, Dunkel IJ (2005) Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol 89(12):1616-1619. doi: 10.1136/bjo.2005.072033
2. Broaddus E, Topham A, Singh AD (2009a) Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93(1):21-23. doi: 10.1136/bjo.2008.138750
3. Broaddus E, Topham A, Singh AD (2009b) Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93(1):24-27. doi: 10.1136/bjo.2008.143842
4. Carcaboso AM, Bramuglia GF, Chantada GL, Fandino AC, Chiappetta DA, de Davila MT, Rubio MC, Abramson DH (2007) Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Investig Ophthalmol Vis Sci 48(8):3761-3767. doi: 10.1167/iovs.06-1152
5. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res Off J Am Assoc Cancer Res 12(6):1859-1867. doi: 10.1158/1078-0432.CCR-05-2019
6. Chantada G, Fandino A, Casak S, Manzitti J, Raslawski E, Schvartzman E (2003) Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 40(3):158-161. doi: 10.1002/mpo.10249
7. Chen J, Huang X, Huang G, Chen Y, Chen L, Song H (2012) Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 27(3):210-220. doi: 10.1089/cbr.2011.1116
8. de Raphelis Soissan A, Berlier P, Claude L, Carrie C, Frappaz D (2012) Papillar thyroid cancer: a rare case of a second primary tumor in retinoblastoma. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie 19(10):1086-1088. doi: 10.1016/j.arcped.2012.07.007
9. Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G (1998) The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol 13(2):225-232
10. Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL (2012) Retinoblastoma. Lancet 379(9824):1436-1446. doi: 10.1016/S0140-6736(11) 61137-9
11. Dunkel IJ, Lee TC, Shi W, Beaverson KL, Novetsky D, Lyden D, Finlay JL, McCormick B, Abramson DH (2007) A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer 49(5):643-648. doi: 10.1002/pbc.21163
12. Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD (2012) Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother CII 61(4):535-547. doi: 10.1007/s00262-011-1121-4
13. Gao YJ, Qian J, Yue H, Yuan YF, Xue K, Yao YQ (2011) Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group. Pediatr Blood Cancer 57(7):1113-1116. doi: 10.1002/pbc.23002
14. Greenwood J, Calder VL (1993) Lymphocyte migration through cultured endothelial cell monolayers derived from the blood-retinal barrier. Immunology 80(3):401-406
15. Hoves S, Sutton VR, Trapani JA (2012) A novel role for granzymes in anti-tumor immunity. Oncoimmunology 1(2):219-221. doi: 10.4161/onci.1.2.18102
16. Jakel CE, Hauser S, Rogenhofer S, Muller SC, Brossart P, Schmidt-Wolf IG (2012) Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol 2012:473245. doi: 10.1155/2012/473245
17. Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A (2011) Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 129(11):1422-1427. doi: 10.1001/archophthalmol.2011.289
18. Kivela T (2009) The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 93(9):1129-1131. doi: 10.1136/bjo.2008.150292
19. Kornacker M, Verneris M, Kornacker B, Ganten T, Scheffold C, Negrin R (2006) The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy 8(1):13-23. doi: 10.1080/14653240500518264
20. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B (1995) The biochemistry of programmed cell death. FASEB J Off Publ Fed Am Soc Exp Biol 9(13):1277-1287
21. Leahey A (2012) A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol Off J Am Soc Clin Oncol 30(10):1023-1024. doi: 10.1200/JCO.2011.39.4254
22. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, Nijman HW (2010) Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 1:CD007287. doi: 10.1002/14651858.CD007287.pub2
23. Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, Wang HX (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14(4):483-493. doi: 10.3109/14653249.2011.649185
24. Malyguine AM, Strobl SL, Shurin MR (2012) Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother CII 61(2):239-247. doi: 10.1007/s00262-011-1148-6
25. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D (2012) Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12(6):673-684. doi: 10.1517/14712598.2012.675323
26. Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T (2013) Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother: CII 62(4):639-652. doi: 10.1007/s00262-012-1366-6
27. Pica A, Moeckli R, Balmer A, Beck-Popovic M, Chollet-Rivier M, Do HP, Weber DC, Munier FL (2011) Preliminary experience in treatment of papillary and macular retinoblastoma: evaluation of local control and local complications after treatment with linear accelerator-based stereotactic radiotherapy with micromultileaf collimator as second-line or salvage treatment after chemotherapy. Int J Radiat Oncol Biol Phys 81(5):1380-1386. doi: 10.1016/j.ijrobp.2010.07.033
28. Pollard TD, Cooper JA (2009) Actin, a central player in cell shape and movement. Science 326(5957):1208-1212. doi: 10.1126/science.1175862
29. Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol Off J Am Soc Clin Oncol 30(10):1034-1041. doi: 10.1200/JCO.2011.36.9744
30. Rand ML, Wang H, Pluthero FG, Stafford AR, Ni R, Vaezzadeh N, Allison AC, Kahr WH, Weitz JI, Gross PL (2012) Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation. J Thrombosis Haemostasis JTH 10(6):1109-1119. doi: 10.1111/j.1538-7836.2012.04716.x
31. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269-281. doi: 10.1038/nri3191
32. Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol Off J Am Soc Clin Oncol 21(12):2415-2432. doi: 10.1200/JCO.2003.06.041
33. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1(3):1458-1461. doi: 10.1038/nprot.2006.238
34. Rizzuti AE, Dunkel IJ, Abramson DH (2008) The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol 126(6):862-865. doi: 10.1001/archopht.126.6.862
35. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673-1679
36. Schottker B, Schmidt-Wolf IG (2011) Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells. Ger Med Sci GMS J 9:Doc18. doi: 10.3205/000141
37. Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, Wu C (2012) Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunoth: CII 61(12):2251-2259. doi: 10.1007/s00262-012-1289-2
38. Shields CL, Shields JA (2010) Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 21(3):203-212. doi: 10.1097/ICU.0b013e328338676a
39. Souza Filho JP, Martins MC, Caissie AL, Torres VL, Fernandes LH, Erwenne CM, Burnier MN Jr (2005) Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression. Clin Exp Ophthalmol 33(3):279-284. doi: 10.1111/j.1442-9071.2005.00991.x
40. Sun S, Li XM, Li XD, Yang WS (2005) Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 20(2):173-180. doi: 10.1089/cbr.2005.20.173
41. Sussman DA, Escalona-Benz E, Benz MS, Hayden BC, Feuer W, Cicciarelli N, Toledano S, Markoe A, Murray TG (2003) Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol 121(7):979-984. doi: 10.1001/archopht.121.7.979
42. Tang S, Li YP, Ying FW, Li YQ, Feng GG, Yi YZ (2004) An experiment study of in vitro induced antitumor immune responses by vaccination of tumor lysate-pulsed dendritic cells to kill SO-RB(50). [Zhonghua yan ke za zhi] Chin J Ophthalmol 40(4):229-233
43. Tolomeo M, Simoni D (2002) Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anti-Cancer Agents 2(3):387-401
44. van der Vijgh WJ (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21(4):242-261
45. Van Echo DA, Egorin MJ, Aisner J (1989) The pharmacology of carboplatin. Semin Oncol 16(2 Suppl 5):1-6
46. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother CII 49(6):335-345
47. Wang YF, Kunda PE, Lin JW, Wang H, Chen XM, Liu QL, Liu T (2013) Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep 29(5):1841-1850. doi: 10.3892/or.2013.2315
48. Wu YG, Wu GZ, Wang L, Zhang YY, Li Z, Li DC (2010) Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo. Med Oncol 27(3):736-742. doi: 10.1007/s12032-009-9277-x
49. Yang B, Lu XC, Yu RL, Chi XH, Liu Y, Wang Y, Dai HR, Zhu HL, Cai LL, Han WD (2012) Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 30(3):115-122. doi: 10.1002/hon.1012
50. Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunoth: CII 62(1):65-73. doi: 10.1007/s00262-012-1311-8
51. Yu J, Zhang W, Jiang H, Li H, Cao S, Ren X (2008) CD4 + T cells in CIKs (CD4 + CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm 23(3):342-354. doi: 10.1089/cbr.2007.0454
52. Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF, Qiu JG (2012) A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J 125(21):3771-3777
53. Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y, Shu Y (2012) The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 138(6):1057-1062. doi: 10.1007/s00432-012-1179-1
54. Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B, Chan HS, Gallie BL (2011) Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol Off J Am Soc Clin Oncol 29(7):845-851. doi: 10.1200/JCO.2010.32.5332
55. Zhong R, Teng J, Han B, Zhong H (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunoth CII 60(10):1497-1502. doi: 10.1007/s00262-011-1060-0